Santhera and ReveraGen Announce New 2 . 5 - year Treatment Data with Vamorolone in Duchenne ...

Two leading drugs have revealed the safety, tolerability and long-term treatment benefits of a controversial muscle dystrophy drug in patients with Duchenne muscular dystrophic disorder (DMD) which have been given the green light for treatment.

Source: apnews.com
Published on 2021-04-28